IL2 and non-small cell lung carcinoma: TG4010, which encodes MUC1 and interleukin 2 (IL2), is a poxvirus-based modified vaccine that enhances the efficacy of chemotherapy in advanced NSCLC (ClinicalTrials.gov identifier: NCT00415818) [92].